1. Home
  2. BCAX vs ANIP Comparison

BCAX vs ANIP Comparison

Compare BCAX & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCAX
  • ANIP
  • Stock Information
  • Founded
  • BCAX 2018
  • ANIP 2001
  • Country
  • BCAX United States
  • ANIP United States
  • Employees
  • BCAX N/A
  • ANIP N/A
  • Industry
  • BCAX
  • ANIP Biotechnology: Pharmaceutical Preparations
  • Sector
  • BCAX
  • ANIP Health Care
  • Exchange
  • BCAX NYSE
  • ANIP Nasdaq
  • Market Cap
  • BCAX 1.0B
  • ANIP 1.2B
  • IPO Year
  • BCAX 2024
  • ANIP N/A
  • Fundamental
  • Price
  • BCAX $12.11
  • ANIP $58.46
  • Analyst Decision
  • BCAX Strong Buy
  • ANIP Buy
  • Analyst Count
  • BCAX 5
  • ANIP 7
  • Target Price
  • BCAX $41.33
  • ANIP $77.33
  • AVG Volume (30 Days)
  • BCAX 603.8K
  • ANIP 257.7K
  • Earning Date
  • BCAX 02-16-2025
  • ANIP 02-27-2025
  • Dividend Yield
  • BCAX N/A
  • ANIP N/A
  • EPS Growth
  • BCAX N/A
  • ANIP N/A
  • EPS
  • BCAX N/A
  • ANIP N/A
  • Revenue
  • BCAX N/A
  • ANIP $555,456,000.00
  • Revenue This Year
  • BCAX N/A
  • ANIP $25.48
  • Revenue Next Year
  • BCAX N/A
  • ANIP $20.24
  • P/E Ratio
  • BCAX N/A
  • ANIP N/A
  • Revenue Growth
  • BCAX N/A
  • ANIP 23.60
  • 52 Week Low
  • BCAX $11.56
  • ANIP $52.50
  • 52 Week High
  • BCAX $28.09
  • ANIP $70.81
  • Technical
  • Relative Strength Index (RSI)
  • BCAX N/A
  • ANIP 62.05
  • Support Level
  • BCAX N/A
  • ANIP $52.74
  • Resistance Level
  • BCAX N/A
  • ANIP $55.21
  • Average True Range (ATR)
  • BCAX 0.00
  • ANIP 1.54
  • MACD
  • BCAX 0.00
  • ANIP 0.48
  • Stochastic Oscillator
  • BCAX 0.00
  • ANIP 98.11

About BCAX BICARA THERAPEUTICS INC

Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.

About ANIP ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

Share on Social Networks: